Every route, with the plan arithmetic shown
Each lane carries a monthly figure with a three-month and, on most, a six-month total beside it. A reader can see the plan arithmetic without a checkout, which is unusual.
The brand pen is priced as a genuine three-step dose ladder rather than a single starting figure — the only brand ladder in this batch.
One oddity the site does not explain: its tirzepatide microdose costs more than its full-dose tirzepatide.
A drug with nothing approved behind it
It sells retatrutide. There is no FDA-approved finished retatrutide product of any kind, so this is not a compounded version of an approved drug — nothing about the molecule has been through an approval.
That is a category difference from compounded semaglutide or tirzepatide, both of which are compounded analogues of approved medicines, and it is worth a reader knowing before comparing prices.
Two prices for one product, and a floor that is not a price
Its catalogue prices the injectable tirzepatide monthly. Its own product page for the same drug prints a different, lower figure with no period at all. Both are recorded here.
Its homepage advertises a floor for single therapies across the whole peptide catalogue. That is not a GLP-1 price, and no GLP-1 lane is anywhere near it. Attaching it to a GLP-1 would be a fabrication, and we have not.
It names its partner pharmacies, states repeatedly that there is no membership or subscription and that nothing is charged unless a prescription is approved, and names no operating company across nine pages including its privacy notice.
PeptidesRx's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $219/mo"Injectable Semaglutide · Every dose, standard or a gentle-start microdose · $219 monthly · $604 for 3 months · $1,116 for 6 months" | September 2026source |
| Semaglutide (compounded-oral) | $208/mo"Oral drops · Semaglutide Oral Drops · Taken under the tongue. Every dose. $208 · 1 mg/mL sublingual · Monthly" | September 2026source |
| Semaglutide (compounded-oral) | $327/mo"Oral melts · Semaglutide Oral Melts · Every dose · $327 monthly · $902 for 3 months · $1,667 for 6 months" | September 2026source |
| Tirzepatide (compounded) | $327/mo"Injectable Tirzepatide · The strongest appetite control we offer · $327 monthly · $902 for 3 months · $1,667 for 6 months" | September 2026source |
| Tirzepatide (compounded) | $263⛔ INCOMPATIBLE WITH ITS OWN CATALOGUE: the product page for the same tirzepatide reads "Tirzepatide $ 263.00" with no period stated, against the $327 monthly its catalogue prints. Both are recorded because the seller publishes both | September 2026source |
| Tirzepatide (compounded) | $329/mo"Injectable Tirzepatide Microdose · A gentler place to start. Every dose. $329 monthly · $908 for 3 months · $1,678 for 6 months" — the microdose costs more than the full dose here | September 2026source |
| Retatrutide (compounded) | $549/mo⛔ RETATRUTIDE HAS NO FDA-APPROVED FINISHED PRODUCT OF ANY KIND — it is not a compounded version of an approved drug. "Injectable Retatrutide · Triple-action GLP-1. Every dose. Offered monthly or for 3 months. $549 monthly · $1,515 for 3 months" | September 2026source |
| Semaglutide (brand) | $475/mo"Ozempic · Brand-name semaglutide pen injector, made by Novo Nordisk. from $475 monthly · 0.25mg $475 · 1mg $675 · 2mg $819" — a real three-step brand dose ladder | September 2026source |
| Semaglutide (brand) | $819/mothe top of the published Ozempic ladder: "0.25mg $475 · 1mg $675 · 2mg $819" | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 240 providers reviewed here are paid partners today; the other 236 are not. See how this works.
See PeptidesRx's current price →Good fit if
- Readers who want every route to both molecules priced on one page.
- Buyers who want three-month and six-month totals shown beside a monthly figure.
- People who want the partner pharmacies named.
Look elsewhere if
- Anyone who wants a seller that does not carry an unapproved molecule.
- Readers who need its catalogue and its product page to agree.
- Buyers who want the operating company named.
- People who need a service-area list or a named clinician.
How this review was verified
- Re-read the homepage, the shop index, the tirzepatide product page and six other product pages on 7 September 2026, comparing requested to effective URLs with a nonsense path against the host in the same run, which returned a 404.
- Recorded both the catalogue figure and the product-page figure for tirzepatide, because the seller publishes both and they disagree.
- Refused to attach the homepage single-therapy floor to any GLP-1 lane, because it is a floor across the whole peptide catalogue.
- Recorded in the price row that retatrutide has no approved finished product of any kind.
- Screened the brand and the trading name against FDA’s live warning-letter datatable with both controls green; the twenty-five rows a word-by-word query returned were each read and none is this company, and an exact-phrase query returned none.